Parametric Portfolio Associates LLC reduced its position in shares of PetMed Express, Inc. (NASDAQ:PETS) by 8.1% during the first quarter, according to its most recent filing with the SEC. The fund owned 62,082 shares of the company’s stock after selling 5,480 shares during the period. Parametric Portfolio Associates LLC owned about 0.31% of PetMed Express worth $1,250,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in PETS. Thrivent Financial for Lutherans raised its position in PetMed Express by 5.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 11,080 shares of the company’s stock worth $256,000 after buying an additional 610 shares in the last quarter. Cardinal Capital Management increased its stake in PetMed Express by 1.8% in the first quarter. Cardinal Capital Management now owns 18,522 shares of the company’s stock valued at $373,000 after buying an additional 322 shares in the last quarter. Comerica Bank increased its stake in PetMed Express by 6.2% in the fourth quarter. Comerica Bank now owns 21,761 shares of the company’s stock valued at $495,000 after buying an additional 1,266 shares in the last quarter. Karp Capital Management Corp purchased a new stake in PetMed Express during the first quarter valued at approximately $496,000. Finally, New Jersey Better Educational Savings Trust purchased a new stake in PetMed Express during the first quarter valued at approximately $504,000. 79.12% of the stock is currently owned by hedge funds and other institutional investors.
Shares of PetMed Express, Inc. (NASDAQ PETS) traded down 1.24% during mid-day trading on Tuesday, reaching $46.94. The company had a trading volume of 340,332 shares. PetMed Express, Inc. has a one year low of $18.90 and a one year high of $50.90. The stock has a market capitalization of $952.51 million, a P/E ratio of 36.11 and a beta of 0.99. The firm has a 50 day moving average of $43.79 and a 200-day moving average of $30.51.
PetMed Express (NASDAQ:PETS) last posted its earnings results on Monday, July 24th. The company reported $0.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.07. PetMed Express had a net margin of 10.34% and a return on equity of 28.67%. The firm had revenue of $79.66 million during the quarter, compared to the consensus estimate of $77.32 million. During the same quarter last year, the firm earned $0.32 EPS. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. Analysts forecast that PetMed Express, Inc. will post $1.44 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, August 18th. Shareholders of record on Monday, August 7th will be paid a $0.20 dividend. The ex-dividend date is Thursday, August 3rd. This represents a $0.80 annualized dividend and a dividend yield of 1.68%. PetMed Express’s dividend payout ratio (DPR) is 61.54%.
Several brokerages recently issued reports on PETS. Noble Financial reiterated a “hold” rating on shares of PetMed Express in a report on Wednesday, July 26th. Northcoast Research upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 price objective for the company in a research note on Monday, July 24th. Craig Hallum downgraded PetMed Express from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Zacks Investment Research upgraded PetMed Express from a “hold” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a research note on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. PetMed Express currently has an average rating of “Hold” and a consensus price target of $35.00.
In other PetMed Express news, Director Robert C. Schweitzer sold 2,500 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.18, for a total value of $122,950.00. Following the completion of the transaction, the director now owns 88,834 shares in the company, valued at $4,368,856.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ronald J. Korn sold 5,000 shares of the business’s stock in a transaction on Friday, July 28th. The stock was sold at an average price of $48.18, for a total transaction of $240,900.00. Following the completion of the transaction, the director now owns 67,333 shares of the company’s stock, valued at approximately $3,244,103.94. The disclosure for this sale can be found here. In the last 90 days, insiders sold 19,333 shares of company stock valued at $949,730. Insiders own 4.00% of the company’s stock.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
